Diagnosis of Myasthenia Gravis is by using –
**Core Concept**
Myasthenia Gravis (MG) is an autoimmune disorder characterized by the production of antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction, leading to impaired neurotransmitter release and subsequent muscle weakness.
**Why the Correct Answer is Right**
The correct answer is based on the principle that MG diagnosis involves identifying the presence of these autoantibodies. The use of serological tests, such as the Radioimmunoprecipitation assay (RIA) or Enzyme-Linked Immunosorbent Assay (ELISA), allows for the detection of these antibodies in patient sera. These tests rely on the binding of patient antibodies to AChR-coated plates, which is then detected using a secondary antibody and a colorimetric or radioactive label. This process enables the quantification of AChR-binding antibodies, providing a diagnostic criterion for MG.
**Why Each Wrong Option is Incorrect**
**Option A:** This option may refer to Electromyography (EMG), which can help identify muscle denervation and reinnervation patterns, but it is not a specific diagnostic test for MG.
**Option B:** This option may refer to Imaging studies, such as Chest X-rays or CT scans, which can reveal thymic abnormalities or other structural changes, but they are not diagnostic for MG.
**Option C:** This option may refer to Repetitive Nerve Stimulation (RNS), which can demonstrate abnormal neuromuscular transmission, but it is not a definitive diagnostic test for MG.
**Clinical Pearl / High-Yield Fact**
A key clinical correlation to remember is that about 10-15% of MG patients have thymus tumors, and up to 70% have thymic hyperplasia, making thymectomy a potential treatment option for some patients.
**Correct Answer: A. Serological tests for AChR-binding antibodies.**